Egypt Cardiovascular Diseases Therapeutics Market Report 2022 to 2030

Egypt Cardiovascular Diseases Therapeutics Market Analysis

$ 3999

The Egypt cardiovascular disease therapeutics market is expected to witness growth from $455 Mn in 2022 to $889 Mn in 2030 with a CAGR of 8.72% for the year 2022-2030. The increasing elderly population in Egypt and the government initiatives like Back to Rhyth and the Nile Heart Challenge to increase awareness about cardiovascular disease in Egypt are the major growth drivers of the market. The Egypt cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Copad Pharma, Menarini Pharmaceutical, and Novartis are the major players in the Egypt cardiovascular disease therapeutics market.

ID: IN10EGPH033 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Dr. Parul Choudhary

Buy Now

Egypt Cardiovascular Disease Therapeutics Market Executive Analysis

The Egypt cardiovascular disease therapeutics market size is at around $455 Mn in 2022 and is projected to reach $889 Mn in 2030, exhibiting a CAGR of 8.72% during the forecast period. To address healthcare requirements, Egypt's Universal Health Insurance System (UHIS) is bringing the private sector on board alongside the public sector, which essentially represents a "paradigm shift" in healthcare service delivery and financing, reported the World Bank. According to healthcare finance experts, private healthcare spending will likely double by 2025 due to the UHIS. The UHIS will unlock a huge healthcare market segment, adding that their market research anticipates private investments to more than double to $10.42 Bn by 2025, from $5 Bn in 2019. According to the report, Egypt's absence of a thorough regulatory system results in obstacles and drawn-out, challenging procedures that make entry into the private healthcare sector challenging.

According to World Health Organization data, cardiovascular diseases account for 46% of all fatalities in Egypt, making them the main cause of mortality. Statins are extremely powerful medications that lower serum cholesterol, avoiding coronary heart disease (CHD). Among the statins that are readily accessible are atorvastatin, pravastatin, simvastatin, and rosuvastatin. One of the most effective and frequently given statins in Egypt is rosuvastatin (Crestor). The effectiveness and safety of generic statins are still an important matter, even though their bioequivalence to brand-name medications led to their approval. It is strongly recommended to increase a statin's maximum tolerated dose until it reaches the target level designated for each risk group. It is strongly advised to combine a statin with ezetimibe if the highest permitted dose is insufficient to reach the required levels. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor should be added to a statin and ezetimibe regimen in patients who are at a very high risk of not meeting their objective.

Egypt Cardiovascular Disease Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

With risk factors like obesity, smoking, and hypertension on the increase, cardiovascular disease is becoming more prevalent in Egypt. As a result, there is now a greater need for efficient therapeutics to control and treat CVD. The Egypt cardiovascular disease therapeutics market is expanding in part due to Egypt's ageing population. Cardiovascular disease is more likely to strike older people, which has increased the demand for drugs to control and treat the condition. The growing prevalence of cardiovascular disease in Egypt is being addressed by government efforts. This includes implementing programs into place to raise awareness of CVD; two examples of government efforts to do so are Back to Rhythm and the Nile Heart Challenge.

Market Restraints

In some areas of Egypt, especially in rural areas, access to healthcare is restricted. Access to CVD therapeutics and medical devices may become challenging as a result, which may restrain Egypt's cardiovascular disease therapeutics market expansion. Some patients, especially those who lack insurance or have inadequate insurance, may find the expense of CVD medications to be prohibitive. This might reduce the need for CVD treatments and slow market expansion. Some CVD medications have side effects, which can make patients less likely to follow their therapy plans. This may hinder the efficacy of CVD treatments and slow Egypt's cardiovascular disease therapeutics market expansion.

Competitive Landscape

Key Players

IBnsina Pharma (EGY)
Liptis (EGY)
Ateco Pharma (EGY)
Copad Pharma (EGY)
Menarini Pharmaceutical (EGY)
Novartis
Mylan
Teva Pharmaceutical
Zydus
Pfizer

Notable Deals

July 2022- To render patients with atherosclerotic cardiovascular disease (ASCVD) the best care possible, pharmaceutical behemoth Novartis Pharma Egypt and Cleopatra Hospitals Group (CHG), Egypt's top provider of medical and healthcare services, have formed a strategic alliance. According to the agreement, Novartis Pharma Egypt and Cleopatra Hospitals Group will offer patients with cardiovascular diseases the best care available, including the most recent treatments and top-notch services throughout their treatment.

Healthcare Policies and Regulatory Landscape

All Egyptians now have access to basic medical services, including treatment for cardiovascular disease (CVD), thanks to Egypt's implementation of a universal health coverage scheme. Additionally, the government has put in place a national health insurance program that covers a variety of medical services, including treatment for CVD. The goal of this system is to guarantee that everyone in Egypt has access to cost-effective, high-quality healthcare. The Egyptian government has put in place several initiatives to support CVD prevention and early diagnosis. The promotion of healthy living choices includes screening programs, public health initiatives, and community-based interventions.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cardiovascular Disease Therapeutics Segmentation

By Disease Indication (Revenue, USD Billion):

Hypertension
Coronary Artery Disease
Hyperlipidaemia
Arrhythmia
Others

By Drug Type (Revenue, USD Billion):

Antihypertensive
Anticoagulants
Antihyperlipidemic
Antiplatelet Drugs
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Drug Classification (Revenue, USD Billion):

Branded Drugs
Generic Drugs

By Mode of Purchase (Revenue, USD Billion):

Prescription-Based Drugs
Over-The-Counter Drugs

By End Users (Revenue, USD Billion):

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.